NICE Agrees to Allow Ofev Therapy for Non-IPF Patients in UK22 Oct 2021 19:12
Clinicians in the U.K. will now be able to prescribe the antifibrotic medicine Ofev (nintedanib) to people with non-idiopathic pulmonary fibrosis (PF) under a new decision by the National Institute for Health and Care Excellence (NICE).
That decision came following a five-year campaign led by the U.K. charity Action for Pulmonary Fibrosis — and supported by patients, families, and pulmonary disease specialists.
“This is a game changer for patients with progressive fibrosis,” Nazia Chaudhuri, PhD, a consultant respiratory physician at Manchester University National Health Service (NHS) Foundation Trust, said in a press release. “I am absolutely delighted with the NICE decision to be able to give life-changing antifibrotic therapy to all patients with progressive lung fibrosis.”
The NICE decision was welcomed by both patients and clinicians.
“This news means everything to me,” said Carol Fielding, a PF patient from Bolton, “It’s about seeing my young grandchildren reach more of their milestones and making some more memories for them. It’s about maybe living long enough that even the younger ones might remember me.”
https://pulmonaryfibrosisnews.com/2021/10/22/nice-agrees-to-allow-ofev-therapy-for-non-ipf-patients-in-uk/
Nfx Rns from March 2021
The study, performed in collaboration with the Newcastle Fibrosis Research Group, a top level multi-disciplinary research group of Newcastle University, UK, examined both the anti-fibrotic and anti-inflammatory potential of NXP002 in combination with the current SOC therapies, pirfenidone or nintedanib, using human precision cut lung slices taken from a single IPF donor.
The preliminary data from this study shows that the combination of NXP002 with SOC provided strong evidence of additional effects compared to either SOC alone on both fibrotic and inflammatory markers. In addition, the results showed evidence of similar or better activity of lower doses of SOC in combination with NXP002, compared to higher doses of SOC alone, indicating a potential for a dose-sparing effect of the combination. These data supplement the previously reported study of NXP002 in the same preclinical model where positive effects were seen when NXP002 was dosed alone and now there is strong data in combination with SOC therapy.
Dr Lee Borthwick, Senior Lecturer in Fibrosis Biology at the Newcastle Fibrosis Research Group, Newcastle University, said: "The data from this most recent study of Nuformix's drug candidate, NXP002, are very encouraging in combination with current IPF drugs and show clear attenuation of both fibrosis and inflammatory markers in combination with pirfenidone or nintedanib. This reinforces previous work done in our laboratories on this compound."
Sign In
Follow the stocks
